Abstract | PURPOSE: PATIENTS AND METHODS: Thirty-seven LGG patients with IDH-wt and TERTp-mut were randomly allocated to either RT alone treatment (RT group, n = 18; 60 Gy in 30 daily fractions) or RT concurrent with TMZ (75 mg/m2/d, 7 d/week) followed by adjuvant TMZ (CRT group, n = 19). The median follow-up duration was 17 months. Log-rank test was used for OS and PFS comparisons. RESULTS: The 1-year OS rate was 94.1% [95% confidence interval (CI) 82.9-100] in the CRT group and 74.6% (95% CI, 52.9-96.4) in the RT group. The median OS values in the CRT and RT groups were statistically different [25 vs. 17 months, respectively; hazard ratio (HR) 0.271; 95% CI, 0.092-0.793; P = 0.017], while PFS values were not (16 vs. 7 months, respectively; HR, 0.917; 95% CI, 0.397-2.120; P = 0.840). Multivariate analysis indicated that CRT treatment and female sex were associated with significantly longer OS (P = 0.001, P = 0.016, respectively). CONCLUSION: CRT treatment for IDH-wt/TERTp-mut grade II/III gliomas resulted in significantly longer OS than RT alone. Female sex was a significant favorable prognostic factor.
|
Authors | Xiaoguang Qiu, Yidong Chen, Zhaoshi Bao, Li Chen, Tao Jiang |
Journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
(Radiother Oncol)
Vol. 167
Pg. 1-6
(02 2022)
ISSN: 1879-0887 [Electronic] Ireland |
PMID | 34902368
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Isocitrate Dehydrogenase
- TERT protein, human
- Telomerase
- Temozolomide
|
Topics |
- Brain Neoplasms
(genetics, therapy)
- Chemoradiotherapy
- Female
- Glioma
(genetics, therapy)
- Humans
- Isocitrate Dehydrogenase
(genetics)
- Male
- Mutation
- Prospective Studies
- Telomerase
(genetics)
- Temozolomide
(therapeutic use)
- World Health Organization
|